EUVIMEDOpdag EUVIMED
Crossref

Perceived comfort with migraine treatments and control of migraine symptoms: Results from the Headache Assessment via Digital Platform in United States study

Kevin M Spiegler, Ali Ezzati iD, Kristina M Fanning, Ryan Bostic, Alexandre Urani, François Cadiou, Richard B Lipton, Angeliki Vgontzas iD

Headache: The Journal of Head and Face Pain · 2026

DOI: 10.1111/head.70165 ↗

At a glance

Journal article in Headache: The Journal of Head and Face Pain, 2026. Written by Kevin M Spiegler and 7 co-authors. Institution: Department of Neurology, NYU Langone Health, New York, New York, USA. Major MEDLINE topics: Migraine Disorders, Patient Satisfaction. Cited 1 times so far (Crossref); 63 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

This study was conducted to identify patient characteristics and medication factors associated with perceived comfort with migraine treatments and control of migraine symptoms.

Background

Patient perceptions of migraine treatment influence adherence and outcomes, yet little is known about their underlying drivers. Our study objective was to identify clinical features of migraine associated with comfort and perceived control of symptoms, and medication classes associated with higher patient comfort and efficacy.

Methods

Participants in the Headache Assessment via Digital Platform in United States (HeAD‐US) study completed a cross‐sectional survey on demographics, migraine burden, mood, disability, and medication use between September and November 2023. Comfort and control were defined using corresponding items from the Migraine Treatment Optimization Questionnaire and categorized as “high” or “low.” We compared patient characteristics, clinical features, and medication classes by reported comfort and control.

Results

Among 5717 participants (mean age, 41.7 ± 13.0 years; 92.1% female), 58.5% reported high comfort with migraine treatments, whereas only 27.5% reported high control of migraine symptoms. High comfort was associated with fewer monthly headache days (mean, 9.9 vs. 14.2; p < 0.001), lower migraine symptom severity (median Migraine Symptom Severity Score 18 vs. 19; p < 0.001), and lower disability (Migraine Disability Assessment Score, severe: 72.7% vs. 91.2%; p < 0.001) and mood symptom scores (Patient Health Questionnaire‐4 severe: 9.5% vs. 21.0%; p < 0.001), as well as income, education, and employment status. High perceived control showed similar associations with monthly headache days (mean, 9.0 vs. 12.7; p < 0.001), migraine severity (median Migraine Symptom Severity Score, 18 vs. 19; p < 0.001), disability (severe: 66.0 vs. 85.8; p < 0.001), and mood symptoms (severe: 7.6 vs. 16.9; p < 0.001), and was associated with employment status but not income or education. Among those on monotherapy, gepants and triptans were associated with higher comfort and efficacy than over the counter medications or opioids/barbiturates/ergots. For preventive therapy, β blockers and botulinum toxin were associated with the lowest perceived comfort and efficacy.

Conclusion

Perceived comfort and control were linked to headache frequency, severity and disability, and mood symptoms. Medication class use influenced perceptions, with gepants and triptans rated most favorably. These findings underscore the importance of incorporating patient perspectives into treatment planning, with particular attention to mood, disability, and choice of medication.

Subjects

MeSH terms (MEDLINE)

Migraine DisordersPatient SatisfactionHumansFemaleAdultMiddle AgedCross-Sectional StudiesUnited StatesMaleSurveys and QuestionnairesAnalgesics

Author keywords

MigraineMigraine disabilityMigraine therapyPatient‐reported outcomesTreatment optimizationTreatment satisfaction

Substances

Analgesics

Authors and institutions

  • Department of Neurology, NYU Langone Health, New York, New York, USA.
  • Department of Neurology, University of California, Irvine, Irvine, California, USA.
  • Mist Research, Wilmington, North Carolina, USA.
  • APTAR LLC, Crystal Lake, Illinois, USA.
  • Department of Neurology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
  • Department of Neurology, Harvard Medical School, Mass General Brigham, Boston, Massachusetts, USA.

ORCID profiles: Ali Ezzati, Angeliki Vgontzas

Cite

APA

Spiegler, K. M., Ezzati, A., Fanning, K. M., Bostic, R., Urani, A., Cadiou, F., Lipton, R. B., & Vgontzas, A. (2026). Perceived comfort with migraine treatments and control of migraine symptoms: Results from the Headache Assessment via Digital Platform in United States study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.70165

Vancouver

Spiegler KM, Ezzati A, Fanning KM, Bostic R, Urani A, Cadiou F, et al. Perceived comfort with migraine treatments and control of migraine symptoms: Results from the Headache Assessment via Digital Platform in United States study. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70165

BibTeX
@article{Spiegler2026,
  author = {Spiegler, Kevin M and Ezzati, Ali and Fanning, Kristina M and Bostic, Ryan and Urani, Alexandre and Cadiou, François and Lipton, Richard B and Vgontzas, Angeliki},
  title = {Perceived comfort with migraine treatments and control of migraine symptoms: Results from the Headache Assessment via Digital Platform in United States study},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  doi = {10.1111/head.70165}
}
Start for free →